Ftse Mib
34.830,17
0,98%
DAX
18.684,50
1,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
68.899,57
1,70%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Oasmia Pharmaceuticals AB (OASM) Oasmia Pharmaceuticals AB (OASM) Notizie

OASM

Oasmia Pharmaceuticals AB (OASM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OASM
DataOraFonteTitoloSimboloCompagnia
07/03/202214:35Business WireCORRECTING and REPLACING Whiting and Oasis to Combine in $6.0 Billion Merger of Equals TransactionNASDAQ:OASMOasmia Pharmaceuticals AB
07/03/202213:20Business WireWhiting and Oasis to Combine in $6.0 Billion Merger of Equals TransactionNASDAQ:OASMOasmia Pharmaceuticals AB
27/11/201915:54Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:OASMOasmia Pharmaceuticals AB
21/11/201915:41Edgar (US Regulatory)Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)NASDAQ:OASMOasmia Pharmaceuticals AB
23/08/201914:01Edgar (US Regulatory)Notice of Termination of a Foreign Private Issuer's Registration of a Class of Securities Under Section 12(b) (15f-12b)NASDAQ:OASMOasmia Pharmaceuticals AB
21/08/201922:06Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:OASMOasmia Pharmaceuticals AB
13/08/201912:03Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme...NASDAQ:OASMOasmia Pharmaceuticals AB
13/08/201912:00Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OASMOasmia Pharmaceuticals AB
08/08/201922:15Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OASMOasmia Pharmaceuticals AB
20/11/201808:00GlobeNewswire Inc.New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been grantedNASDAQ:OASMOasmia Pharmaceuticals AB
03/10/201809:00GlobeNewswire Inc.Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with LymphomaNASDAQ:OASMOasmia Pharmaceuticals AB
21/09/201809:20GlobeNewswire Inc.Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European UnionNASDAQ:OASMOasmia Pharmaceuticals AB
14/09/201822:13Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:OASMOasmia Pharmaceuticals AB
31/08/201822:09Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:OASMOasmia Pharmaceuticals AB
18/05/201822:09Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3/a)NASDAQ:OASMOasmia Pharmaceuticals AB
30/04/201822:19Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:OASMOasmia Pharmaceuticals AB
11/04/201822:07Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:OASMOasmia Pharmaceuticals AB
14/02/201815:41Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:OASMOasmia Pharmaceuticals AB
01/11/201720:24Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:OASMOasmia Pharmaceuticals AB
08/08/201713:00GlobeNewswire Inc.Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in RussiaNASDAQ:OASMOasmia Pharmaceuticals AB
14/06/201713:00GlobeNewswire Inc.Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS marketsNASDAQ:OASMOasmia Pharmaceuticals AB
13/02/201722:39Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:OASMOasmia Pharmaceuticals AB
23/01/201713:00GlobeNewswire Inc.Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary DivisionNASDAQ:OASMOasmia Pharmaceuticals AB
09/01/201721:22Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:OASMOasmia Pharmaceuticals AB
21/12/201613:00GlobeNewswire Inc.Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)NASDAQ:OASMOasmia Pharmaceuticals AB
07/12/201615:30GlobeNewswire Inc.Oasmia Pharmaceutical AB’s Warrant Programs Fully SubscribedNASDAQ:OASMOasmia Pharmaceuticals AB
02/12/201616:05GlobeNewswire Inc.Interim report for the period May - October 2016NASDAQ:OASMOasmia Pharmaceuticals AB
22/11/201613:49GlobeNewswire Inc.Communiqué from Extraordinary General Meeting 2016NASDAQ:OASMOasmia Pharmaceuticals AB
02/11/201612:24GlobeNewswire Inc.Nexttobe Extends Loan to Oasmia PharmaceuticalNASDAQ:OASMOasmia Pharmaceuticals AB
01/11/201622:19GlobeNewswire Inc.Oasmia Pharmaceutical Announces Change in OwnershipNASDAQ:OASMOasmia Pharmaceuticals AB
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OASM

La tua Cronologia

LSE
49BI
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network